Clinical trial: NCT05185713
Section: Confidentiality
Subsections: 8. Confidentiality Measures

The results of this clinical  are only used for scientific research purposes. Therefore, your participation in the  and your personal data during the  are confidential and will be protected 4 / 7 in accordance with the law. Your name and identity will not be disclosed, and your name will not appear in any research reports and public publications. The hospital ethics committee and researchers have the right to access all your research data, including clinical observation tables, experimental data, etc.
Clinical trial: NCT05185713
Section: Purpose of Research
Subsections: 1. Research Background|2. Research Purpose (With Clear Objectives)

Cervical cancer is the fourth most common gynecological malignancy in the world, caused by carcinogenic human papillomavirus[1]. According to the statistics of the World Health Organization in 2018, there are nearly 570, 000 new cases of cervical cancer and about 311, 000 deaths worldwide every year. There are 106, 000 new cases of cervical cancer and about 48, 000 deaths in China every year. In recent years, a lot of data show that the incidence rate of cervical cancer in young women is increasing gradually. Cervical cancer is becoming younger and younger[2], which poses a great threat to the health of women.  
At present, the etiology of cervical cancer is not clear. Studies at home and abroad shew that the occurrence of cervical cancer is related to the age of first sexual intercourse, the number of sexual partners, the age and frequency of first delivery, personal hygiene conditions, smoking, oral contraceptives and other factors[3-5]. It has been recognized that the persistent infection of high-risk human papillomavirus (HR-HPV) is the necessary conditions for cervical intraepithelial neoplasia (cervical intraepithelial neoplasia, CIN) and carcinogenesis. The progression from HPV infection to cervical cancer is slow and complex, which takes about 5-10 years, and only few patients eventually develop cervical precancerous or cancerous. Therefore, there may be other carcinogenic factors or cooperate with HPV in this process[6-7]. The factors increase the susceptibility of cervical epithelial cells to HPV, and increased expression of HPV virus. Therefore ensure the persistence of HPV infection, and finally lead to cancer. As an important factor to maintain the stability of vaginal microenvironment, whether vaginal flora plays a certain role in the process of HR-HPV continuous infection has always been concerned.

2.1 To explore the correlation between vaginal flora and its metabolites and cervical cancer, and to build a risk assessment model of cervical cancer pathogenesis; 2.2 Explore the mechanism of the development and conversion of vaginal flora and its metabolites in cervical cancer, and construct a prediction model of cervical cancer outcome; 2.3 Screen the biomarkers related to the incidence of cervical cancer and therefore provide new ideas for the screening and treatment of cervical cancer.